← Back to news
Clinical trialUNITERAREFriday, April 3, 2026 · April 3, 2026

New Recruiting Trial: Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

WHY IT MATTERS

This trial is specifically designed for women and girls with hemophilia A undergoing surgery — a population that often receives less research attention than males with the same condition.

This is a clinical trial testing a blood clotting medicine called Nuwiq in women and girls with hemophilia A who need surgery. Hemophilia A is a rare bleeding disorder where the body doesn't make enough of a protein that helps blood clot. The trial will study how well Nuwiq works and what dose is best for these patients during surgical procedures.

NCT ID: NCT05936580 Title: Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery Status: RECRUITING Phase: PHASE4 Sponsor: Octapharma Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT05936580 Source: UniteRare clinical trials database

YOU CAN ACT ON THIS

If you are a woman or girl with hemophilia A who may need surgery, check the trial website (clinicaltrials.gov/study/NCT05936580) to see if you meet eligibility requirements and contact the study team about enrolling.

Find clinical trials →Learn more ↗
hemophilia asurgerywomen's healthclinical trialfactor viii

Related conditions

Hemophilia A